

REQUEST FOR CONTINUED EXAMINATION (RCE) TRANSMITTAL	Application No.: 10/539,385 Filing Date: June 16, 2005 First Named Inventor: Mark James BAMFORD Group Art Unit: 1624 Examiner: B.L. Coleman Attorney Docket No.: P33159USW
Subsection (b) of 35 U.S.C. § 132, effective on May 29, 2000, provides for continued examination of an utility or plant application filed on or after June 8, 1995. See The American Inventors Protection Act of 1999 (AIPA).	Confirmation No. 4857 Filed Via Fax on: July 10, 2009

FAX RECEIVED

JUL 10 2009

OFFICE OF PETITIONS

This is a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 of the above-identified application.

NOTE: 37 C.F.R. § 1.114 is effective on May 29, 2000. If the above-identified application was filed prior to May 29, 2000, applicant may wish to consider filing a continued prosecution application (CPA) under 37 C.F.R. § 1.53 (d) (PTO/SB/29) instead of RCE to be eligible for the patent term adjustment provisions of the AIPA. See Changes to Application Examination and Provisional Application Practice, Final Rule, 65 Fed. Reg. 50092 (Aug 16, 2000); Interim Rule, 65 Fed. Reg. 14865 (Mar. 20, 2000) 1233 Off. Gaz. Pat. Office 47 (April 11, 2000), which established RCE practice.

1. Submission required under 37 C.F.R. § 1.114

- a. ☐ Previously submitted
- i. ☐ Consider the amendment(s)/reply under 37 C.F.R. § 1.116 previously filed on _____
 (Any unentered amendment(s) referred to above will be entered)
- ii. ☐ Consider the arguments in the Appeal Brief or Reply Brief previously filed on _____
- iii. ☐ Other _____
- b. ☒ **Enclosed**
- i. ☐ Amendment/Reply _____ pages
- ii. ☐ Affidavit(s)/Declaration(s) _____ pages
- iii. ☒ Information Disclosure Statement (IDS) 1 pages
- iv. ☒ Form PTO 1449 1 pgs. & 1 reference attached
- v. ☒ Other: Amendment for Correction of Inventorship Pursuant to 37 C.F.R. § 1.48(b) and Petition for Withdrawal of Patent from Issue

2. Miscellaneous

- a. ☐ Suspension of action on the above-identified application is requested under 37 C.F.R. § 1.103 (c) for a period of _____ months. (Period of suspension shall not exceed 3 months; Fee under 37 C.F.R. § 1.17(f) required)
- b. ☐ Other _____

3. FEES The RCE fee under 37 C.F.R. § 1.117(c) is required by 37 C.F.R. § 1.114 when the RCE is filed.

- a. ☒ The Director is hereby authorized to charge the following fees or credit any overpayments, to **Deposit Account No. 19-2570.**

☒ General Authorization to charge any and all fees under 37 CFR 1.16 or 1.17, including petitions for extensions of time, relating to this application. (37 CFR 1.136(a)(3))

- i. ☒ RCE fee required under 37 C.F.R. § 1.17(e). **\$810.00**
- ii. ☐ () Month Extension of time fee (37 C.F.R. §§ 1.136 and 1.17) **\$0.00**
- iii. ☒ Additional Fees **\$260.00**

- iv. ☒ **Total Fee to be charged to Deposit Account 19-2570** **\$1,070.00**


07/14/2009 LDIEPI 00000001 192570 10539385

02 FC:1001 810.00 DA

CORRESPONDENCE ADDRESS

Address GLAXOSMITHKLINE
 Corporate Intellectual Property - UW2220
 P.O. Box 1539
 King of Prussia, PA 19406-0939
 Telephone (610) 270-5030 Facsimile (610) 270-5090

RESPECTFULLY SUBMITTED,

Signature
NAME

 Duke M. Fitch

Registration No. 63,058

Customer No. 20462

**GlaxoSmithKline**

GlaxoSmithKline

Corporate Intellectual Property-US

P.O. Box 1539

709 Swedeland Road

King of Prussia, PA

19406-0939

Tel: 610-270-5030

Fax: 610-270-5090

www.gsk.com

FAX**To** Cheryl Baylor Gibson**Fax** 571-273-0025**From** Duke M. Fitch**Tel** (610) 270-5030**Date** July 10, 2009 **Pages including cover** 41**Subject** U.S. Serial No. 10/539,385 (Attorney Docket No. 33159USW)**FAX RECEIVED****JUL 10 2009****OFFICE OF PETITIONS**

Ms. Gibson,

Attached are the following documents:

RCE Transmittal (1 page)

Amendment for Correction of Inventorship Pursuant to 37 C.F.R. §1.48(b) (2 pages)

Petition for Withdrawal of Patent from Issue (2 pages)

Information Disclosure Statement (1 page)

PTO 1449 Form (1 page)

WO 2004/035544 (33 pages)

Thank you.

Duke M. Fitch
Agent for Applicants
Registration No. 63,058

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error, please contact us immediately by telephone so that we can arrange for its return.